For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Sun Pharma enters into tripartite agreement for brain therapy

By Religare
|

Leading pharma firm, Sun Pharmaceutical Industries has entered into a tripartite research and option agreement with Israel-based Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke; as well as glioblastoma, a lethal brain cancer.

As per the signed triparty agreement, Sun Pharma will have the first right to develop these additional indications. Sun Pharma will have the exclusive option to conduct further development of the enzyme after completion of the preclinical studies. The company will have commercial rights to this product globally. It will also fund all future studies to be conducted on the enzyme," the company informed in a filing to the Bombay Stock Exchange.

 

The tripartite research collaboration agreement has been signed between Sun Pharma, Yeda Research & Development Company, Ltd. (the commercial arm of the Weizmann Institute of Science), and Fundacion Ramn Domnguez (on behalf of IDIS).

Commenting on its collaboration with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela, Sun Pharma Sr. Vice President Kirti Ganorkar said, "This collaboration is in line with our philosophy of putting patients first. We see our collaboration with world-renowned academic institutions like the Weizmann Institute of Science and the Health Research Institute of Santiago de Compostela enabling new projects on breakthrough products to address current unmet medical needs."

Meanwhile, shares of the company were trading at Rs 746.85 apiece, down 1.57 per cent from the previous close at 10:12 hours on BSE.

Story first published: Thursday, December 10, 2015, 12:10 [IST]
Company Search
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more